


Curriculum Vitae

Name	YAP, Yoon-Sim	
Current Position & Affiliation	Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore, Associate Professor at Duke-National University Singapore	
Country	Singapore	

Educational Background

MBBS and PhD: University of Adelaide, Australia

FRACP: Royal Australasian College of Physicians (RACP), Medical Oncology

Professional Experience

Upon completion of her specialist training in medical oncology in Australia, she undertook a research fellowship with the Breast Unit at the Royal Marsden Hospital, London, before relocating to National Cancer Centre Singapore.

Professional Organizations

Singapore Society of Oncology

European Society of Medical Oncology Breast Faculty Member

Japanese Society of Medical Oncology International Steering Committee Member

Main Scientific Publications

1. Klefogiannis D, Ho D, Liew JX, Poon PSY, Gan A, Ng RC, Tan BK, Tay KH, Lim SH, Tan GS, Shih CC, Lim TK, Lee AS, Tan IB, Yap YS, Ng SB. Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing. *Sci Rep.* 2020 Oct 8;10(1):16774. doi: 10.1038/s41598-020-72818-6.

2. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau CCT, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A. Neratinib + Capecitabine vs Lapatinib + Capecitabine in HER2+ Metastatic Breast Cancer Previously Treated with Two or more HER2-Directed Regimens: Phase III NALA Trial. *J Clin Onc.* 2020 Jul 17;JCO2000147. doi: 10.1200/JCO.20.00147. Online ahead of print
 3. Yap YS, Chiu J, Ito Y, Ishikawa T, Aruga T, Kim SJ, Toyama T, Saeki T, Saito M, Gounaris I, Su F, Ji Y, Han Y, Gazdoui M, Masuda N. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer. *Cancer Sci.* 2020 Jul 3. doi: 10.1111/cas.14554. Online ahead of print.
 4. Lee SC, Shimasaki N, Lim JSJ, Wong AL, Yadav K, Yong WP, Tan LK, Koh LP, Poon MLM, Tan SH, Ow SG, Bharwani L, Yap YS, Foo M, Coustan-Smith E, Sundar R, Tan HL, Chong WQ, Kumarakulasinghe NB, Lieow JLM, Koe PJX, Goh BC, Campana D. Phase I trial of expanded, activated autologous NK cell infusions with trastuzumab in patients with HER2-positive cancers. *Clin Cancer Res.* 2020 Jun 10;clincanres.0768.2020. doi: 10.1158/1078-0432.CCR-20-0768. Online ahead of print.
 5. **Yap YS**, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC. Insights Into Breast Cancer in the East vs the West: A Review. *JAMA Oncol.* 2019;5(10):1489-1496.
-